ReviewLife (Basel, Switzerland)2025
Comparative Effectiveness of Urine vs. Stool Gluten Immunogenic Peptides Testing for Monitoring Gluten Intake in Coeliac Patients: A Systematic Review and Meta-Analysis.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coeliac disease (CD) is a chronic immune-mediated enteropathy triggered by gluten ingestion in genetically predisposed individuals carrying HLA-DQ2 or HLA-DQ8 haplotypes, characterized by small intestinal mucosal damage and systemic manifestations. This systematic review and meta-analysis aimed to compare the effectiveness of urine versus stool GIPS testing for monitoring gluten intake in coeliac patients, providing evidence-based recommendations for clinical practice. A comprehensive literature search was conducted in databases like PubMed and Embase. Studies evaluating urine or stool GIPS testing in coeliac patients were included, focusing on sensitivity, specificity, and patient adherence. The meta-analysis included six studies with a total of 572 participants. The stool GIPS testing demonstrated a pooled sensitivity of 85.1% (95% CI: 79.0-89.9%) and a specificity of 92.5% (95% CI: 88.3-95.6%), making it highly reliable for detecting gluten exposure and ruling out false positives. It also achieved an AUC of 0.9853, indicating excellent diagnostic performance. In contrast, the urine GIPS testing showed a pooled sensitivity of 55.4% (95% CI: 49.6-61.2%) and a specificity of 73.0% (95% CI: 67.4-78.1%), with an AUC of 0.7898. The heterogeneity across the studies was significant (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.